Age: 8.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: Children received their first dose of the primary series with the Moderna bivalent vaccine booster instead of monovalent; Children received their first dose of the primary series with the Moderna bivalent vaccine booster instead of monovalent; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Children received their first dose of the primary series with the Moderna bivalent vaccine booster instead of monovalent), WRONG PRODUCT ADMINISTERED (Children received their first dose of the primary series with the Moderna bivalent vaccine booster instead of monovalent) and NO ADVERSE EVENT (No adverse event) in an 8-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 061F22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Children received their first dose of the primary series with the Moderna bivalent vaccine booster instead of monovalent), WRONG PRODUCT ADMINISTERED (Children received their first dose of the primary series with the Moderna bivalent vaccine booster instead of monovalent) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Children received their first dose of the primary series with the Moderna bivalent vaccine booster instead of monovalent), WRONG PRODUCT ADMINISTERED (Children received their first dose of the primary series with the Moderna bivalent vaccine booster instead of monovalent) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Children received their first dose of the primary series with the Moderna bivalent vaccine booster instead of monovalent) and WRONG PRODUCT ADMINISTERED (Children received their first dose of the primary series with the Moderna bivalent vaccine booster instead of monovalent).    This case for 2nd patient of 3 patients. No concomitant medications were provided. The Pharmacist administered Moderna vaccine to a family and 3 of the children received their first dose of the primary series with the Moderna bivalent vaccine booster.   No other adverse events reported. No treatment medication was provided.   This case was linked to US-MODERNATX, INC.-MOD-2022-664257, US-MODERNATX, INC.-MOD-2022-664266 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-664257: US-MODERNATX, INC.-MOD-2022-664266: